Exendin-4 Ameliorates Lipotoxicity-induced Glomerular Endothelial Cell Injury by Improving ABC Transporter A1-mediated Cholesterol Efflux in Diabetic apoE Knockout Mice
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
ATP-binding cassette transporter A1 (ABCA1), which promotes cholesterol efflux from cells and inhibits inflammatory responses, is highly expressed in the kidney. Research has shown that exendin-4, a glucagon-like peptide-1 receptor (GLP-1R) agonist, promotes ABCA1 expression in multiple tissues and organs; however, the mechanisms underlying exendin-4 induction of ABCA1 expression in glomerular endothelial cells are not fully understood. In this study we investigated the effect of exendin-4 on ABCA1 in glomerular endothelial cells of diabetic kidney disease (DKD) and the possible mechanism. We observed a marked increase in glomerular lipid deposits in tissues of patients with DKD and diabetic apolipoprotein E knock-out (apoE −/− ) mice by Oil Red O staining and biochemical analysis of cholesterol. We found significantly decreased ABCA1 expression in glomerular endothelial cells of diabetic apoE −/− mice and increased renal lipid, cholesterol, and inflammatory cytokine levels. Exendin-4 decreased renal cholesterol accumulation and inflammation and increased cholesterol efflux by up-regulating ABCA1. In human glomerular endothelial cells, GLP-1R-mediated signaling pathways ( e.g. Ca 2+ /calmodulin-dependent protein kinase, cAMP/PKA, PI3K/AKT, and ERK1/2) were involved in cholesterol efflux and inflammatory responses by regulating ABCA1 expression. We propose that exendin-4 increases ABCA1 expression in glomerular endothelial cells, which plays an important role in alleviating renal lipid accumulation, inflammation, and proteinuria in mice with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diabetes in Asia: Epidemiology, Risk Factors, and Pathophysiology
Chan, J. C. N., Malik, V., Jia, W., Kadowaki, T., Yajnik, C. S., Yoon, K.-H., & Hu, F. B. (2009) · JAMA · doi:10.1001/jama.2009.726 · Cited by 1,997
Diabetic nephropathy: diagnosis, prevention, and treatment
Gross, J. L., de Azevedo, M. J., Silveiro, S. P., Canani, L. H., Caramori, M. L., & Zelmanovitz, T. (2005) · Diabetes Care · doi:10.2337/diacare.28.1.164 · Cited by 1,839
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585
Cholesterol, inflammation and innate immunity.
Tall, A. R., & Yvan-Charvet, L. (2015) · Nature Reviews Immunology · doi:10.1038/nri3793 · Cited by 1,479
Kodera, R., Shikata, K., Kataoka, H. U., Takatsuka, T., Miyamoto, S., Sasaki, M., Kajitani, N., Nishishita, S., Sarai, K., Hirota, D., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-2028-x · Cited by 394 · cited 1×
“Glucagon-like peptide-1 receptor (GLP-1R), which is also expressed in kidney tissue (16), and its agonists (17) exert potential renoprotective effects in DKD by decreasing oxidative stress, lipid accumulation, macrophage infiltration, and proinflammatory cytokine release while improving metabolic abnormalities.”
BackgroundGlucose or diabetes activates p38 mitogen-activated protein kinase via different pathways
Igarashi, M., Wakasaki, H., Takahara, N., Ishii, H., Jiang, Z.-Y., Yamauchi, T., Kuboki, K., Meier, M., Rhodes, C. J., & King, G. L. (1999) · Journal of Clinical Investigation · doi:10.1172/jci3326 · Cited by 386 · cited 1×
“In animal studies, ERK1/2 signaling is activated under hyperglycemic conditions in aortic vascular smooth muscle cells in vivo (34, 60) and under high glucose conditions in cultured vascular smooth muscle cells.”
BackgroundFujita, H., Morii, T., Fujishima, H., Sato, T., Shimizu, T., Hosoba, M., Tsukiyama, K., Narita, T., Takahashi, T., Drucker, D. J., et al. (2014) · Kidney International · doi:10.1038/ki.2013.427 · Cited by 336 · cited 2×
“Upstream mechanisms involved in GLP-1-mediated renal protection in diabetes are unclear but may involve activation of cAMP/PKA (52), which is a positive regulator of ABCA1 (18).”
BackgroundThe Macrophage Cholesterol Exporter ABCA1 Functions as an Anti-inflammatory Receptor
Tang, C., Liu, Y., Kessler, P. S., Vaughan, A. M., & Oram, J. F. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.047472 · Cited by 284 · cited 1×
“ABCA1 also inhibits the expression of inflammatory cytokines IL-1β, IL-6, and TNFα in macrophages (12-15), suggesting a potential role in suppressing inflammation.”
BackgroundNagashima, M., Watanabe, T., Terasaki, M., Tomoyasu, M., Nohtomi, K., Kim-Kaneyama, J., Miyazaki, A., & Hirano, T. (2011) · Diabetologia · doi:10.1007/s00125-011-2241-2 · Cited by 259 · cited 1×
“In animal models of diabetes, exendin-4 activates GLP-1R in THP-1 macrophages, thereby increasing ABCA1 expression, enhancing reverse cholesterol transport, and preventing the maturation of oxidized LDL and atherogenic foam cell formation (54,55).”
BackgroundPark, C. W., Kim, H. W., Ko, S. H., Lim, J. H., Ryu, G. R., Chung, H. W., Han, S. W., Shin, S. J., Bang, B. K., Breyer, M. D., et al. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006070778 · Cited by 218 · cited 1×
“Exendin-4 acts directly on GLP-1R to decrease body weight, peri-epididymal fat, 24-h urine volume, and creatinine clearance in diabetic (db/db) mice (51); the renoprotective effects of exendin-4 in patients with DKD have been described (52, 53).”
BackgroundTashiro, Y., Sato, K., Watanabe, T., Nohtomi, K., Terasaki, M., Nagashima, M., & Hirano, T. (2014) · Peptides · doi:10.1016/j.peptides.2013.12.015 · Cited by 149 · cited 1×
“In animal models of diabetes, exendin-4 activates GLP-1R in THP-1 macrophages, thereby increasing ABCA1 expression, enhancing reverse cholesterol transport, and preventing the maturation of oxidized LDL and atherogenic foam cell formation (54,55).”
BackgroundWesterterp, M., Tsuchiya, K., Tattersall, I. W., Fotakis, P., Bochem, A. E., Molusky, M. M., Ntonga, V., Abramowicz, S., Parks, J. S., Welch, C. L., et al. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306670 · Cited by 114
Xing, S.-S., Yang, X.-Y., Zheng, T., Li, W.-J., Wu, D., Chi, J.-Y., Bian, F., Bai, X.-L., Wu, G.-J., Zhang, Y.-Z., et al. (2015) · Vascular Pharmacology · doi:10.1016/j.vph.2015.07.004 · Cited by 99 · cited 1×
“For example, ABCA1 expression is regulated by the PI3K/AKT pathway (32, 59).”
Background
Cited by
Xu, S., Ilyas, I., Little, P. J., Li, H., Kamato, D., Zheng, X., Luo, S., Li, Z., Liu, P., Han, J., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000096 · Cited by 1,142
Signaling pathways of chronic kidney diseases, implications for therapeutics
Yuan, Q., Tang, B., & Zhang, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01036-5 · Cited by 453
Lipotoxicity and Diabetic Nephropathy: Novel Mechanistic Insights and Therapeutic Opportunities
Opazo-Ríos, L., Mas, S., Marín-Royo, G., Mezzano, S., Gómez-Guerrero, C., Moreno, J. A., & Egido, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072632 · Cited by 363
Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease
Mitrofanova, A., Merscher, S., & Fornoni, A. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00741-w · Cited by 356
Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy
Rayego-Mateos, S., Morgado-Pascual, J. L., Opazo-Ríos, L., Guerrero-Hue, M., García-Caballero, C., Vázquez-Carballo, C., Mas, S., Sanz, A. B., Herencia, C., Mezzano, S., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113798 · Cited by 334
Metadata
- Authors
- Yin, Q.-H., Zhang, R., Li, L., Wang, Y.-T., Liu, J.-P., Zhang, J., Bai, L., Cheng, J.-Q., Fu, P., & Liu, F.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 291
- Issue
- 51
- Pages
- 26487-26501
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2543209401
- Cited by
- 66
- References
- 13
- FWCI
- 4.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.